Cantor Fitzgerald Reiterates Overweight on TruBridge, Maintains $13 Price Target
TruBridge Analyst Ratings
TruBridge Financial Analysis: Hold Rating Amidst Mixed Performance and Strategic Growth Initiatives
TruBridge Analyst Ratings
RBC Capital Maintains TruBridge(TBRG.US) With Buy Rating, Raises Target Price to $14
RBC Adjusts Price Target on TruBridge to $14 From $13, Maintains Outperform Rating
RBC Capital Sticks to Their Buy Rating for TruBridge (TBRG)
TruBridge (TBRG) Gets a Hold From Barclays
TruBridge Price Target Raised to $13.00/Share From $11.00 by Cantor Fitzgerald
TruBridge Analyst Ratings
Cantor Fitzgerald Reaffirms Their Buy Rating on TruBridge (TBRG)
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)
Canto Fitzgerald: Reiterates TruBridge (TBRG.US) rating and adjusted from increased holdings to increased holdings, with a target price of $24.00.
TruBridge Analyst Ratings
TruBridge Analyst Ratings
RBC Capital Initiates Coverage On TruBridge With Outperform Rating, Announces Price Target of $13
Barclays Issues a Hold Rating on TruBridge (TBRG)
TruBridge Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on CPSI, Maintains $24 Price Target